Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Human immunodeficiency virus (HIV) II infection category B1
0.060 Biomarker disease BEFREE Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. 12232843 2002
Human immunodeficiency virus (HIV) II infection category B1
0.060 Biomarker disease BEFREE The effect of highly active antiretroviral therapy (HAART) and granulocyte colony stimulating factor (G-CSF) on mean telomere restriction fragment (TRF) length of peripheral blood mononuclear cells (PBMC) was examined in 11 treatment naïve human immunodeficiency virus (HIV)-infected individuals with a CD4+ T-cell count < 350 cells/mm3. 11555394 2001
Human immunodeficiency virus (HIV) II infection category B1
0.060 GeneticVariation disease BEFREE However, plasma HIV RNA changed significantly different between the two groups with the decrease being less pronounced in the G-CSF group (P = 0.02). 10792845 2000
Human immunodeficiency virus (HIV) II infection category B1
0.060 Biomarker disease BEFREE The purpose of this study was to investigate the mobilization and collection of peripheral blood progenitor cells from human immunodeficiency virus (HIV)-infected individuals using granulocyte colony-stimulating factor (G-CSF). 9923453 1999
Human immunodeficiency virus (HIV) II infection category B1
0.060 Biomarker disease BEFREE Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. 9116267 1997
Human immunodeficiency virus (HIV) II infection category B1
0.060 Biomarker disease BEFREE Six patients with human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma receiving chemotherapy (CT) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus granulocyte colony-stimulating factor were sequentially monitored to study the effects of these treatments on their immunologic status (CD4 and CD8 cell counts) and on HIV plasma viremia. 8959247 1996